Regorafenib, a multikinase inhibitor targeting VEGFR 1–3, FGFR 1–2, angiopoietin-1 receptor (TIE2) and alpha and beta PDFRs, was the first agent to be approved as a second-line systemic therapy for advanced HCC following progression with sorafenib. Here, TEK is linked to hepatocellular carcinoma.